Investor Relations

1st QUARTER 2024


Evonik has published its quarterly report Q1 2024 on May 8, 2024. 

You can access further information here.

  • Adj. EBITDA of €522 m clearly above prior year (+28% yoy) – even despite limited macro support so far
  • Drivers of strong Q1 performance: Nutrition & Care with Animal Nutrition and strong Care Solutions portfolio; Specialty Additives with strong operating leverage from volumes coming back
  • Contingency & optimization measures further ramping up; preparation for €400 m “Evonik Tailor Made” savings on track
  • FCF of €127 m well above prior-year quarter, based on improved earnings and continued tight NWC management
  • Outlook range for adj. EBITDA (€1.7 to 2.0 bn) confirmed – Q2 adj. EBITDA expected on Q1 level

Reporting 1st Quarter 2024

Link / PDF
Analyst & Investor Factsheet
Presentation Conference Call

Detailed overview of key financial data (Evonik Financials) - as PDF

Detailed overview of key financial data (Evonik Financials) - as Excel

Quarterly Statement Q1 2024

Investor Relations News Q1 2024

Analysts' consensus* (Vara Research)

Webcast Conference Call Q1 2024
(May 8, 2024, 11.00 am CEST)



Link / PDF

Investor Relations News preliminary results Q1 2024

* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.